SecurityCACQ / Caesars Acquisition Co. (12768T103)
President and CEOGarber Mitchell Alan
IndustryHotels and Motels
Institutional Owners6
Institutional Shares2,143,824 - 1.54%
Common Shares Outstanding138,984,958 shares (as of 2017-06-30)
Institutional Value$ 28,988,000 USD

Institutional Stock Ownership and Shareholders()

CACQ / Caesars Acquisition Co. Institutional Ownership

Caesars Acquisition Co. (NASDAQ:CACQ) has 6 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 2,143,824 shares. Largest shareholders include BlackRock Fund Advisors, BlackRock Institutional Trust Company, N.A., BlackRock Investment Management, LLC, BlackRock Group LTD, BlackRock Advisors LLC, and Americafirst Quantitative Trust - Americafirst Defensive Growth & Income Portfolio, Series 2.
Caesars Acquisition Co. (NASDAQ:CACQ) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds more than 5% of the company and intends to actively pursue a change in business strategy. Schedule 13G indicates a passive investment of over 5%. Green rows indicate new positions. Red rows indicate closed positions. Click the link icon to see the full transaction history.

Embed this chart! (it updates automatically)
<a href="https://fintel.io/so/us/cacq"><img src="https://images.fintel.io/us-cacq-so.png" alt="CACQ / Caesars Acquisition Co. Institutional Ownership"><a>

File DateFormInvestor Opt Prev
Shares
Current
Shares
Change
(Percent)
Prev Value
($1000)
Current Value
($1000)
Change
(Percent)
2017-08-15 13F-HR Americafirst Quantitative Trust - Americafirst Defensive Growth & Income Portfolio, Series 2 8,392 160
2017-02-10 13F-HR BlackRock Investment Management, LLC 193,491 192,586 -0.47 2,403 2,600 8.20
2017-02-10 13F-HR BlackRock Group LTD 18,154 20,593 13.44 225 278 23.56
2017-11-16 13F-HR AMERICAFIRST CAPITAL MANAGEMENT, LLC 8,392 0 -100.00 160 0 -100.00
2017-02-10 13F-HR BlackRock Fund Advisors 1,210,927 1,435,258 18.53 15,040 19,376 28.83
2017-02-10 13F-HR BlackRock Institutional Trust Company, N.A. 450,733 468,748 4.00 5,598 6,328 13.04
2017-02-10 13F-HR BlackRock Advisors LLC 17,347 18,247 5.19 215 246 14.42

Related Articles

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...

Related News Stories

Tracking John Paulson's Paulson & Co. Portfolio - Q1 2018 Update

2018-05-18 seekingalpha
This article is part of a series that provides an ongoing analysis of the changes made to John Paulson's 13F stock portfolio on a quarterly basis. It is based on Paulson's regulatory 13F Form filed on 05/15/2018. Please visit our Tracking John Paulson's Paulson & Co. Portfolio series to get an idea of his investment philosophy and our previous update for the fund's moves during Q4 2017. (1229-10)

Tracking George Soros' Portfolio - Q1 2018 Update

2018-05-17 seekingalpha
Soros' 13F portfolio value increased from $4.37B to $6.16B this quarter. The number of positions increased from 196 to 219. (1403-10)

Caesars Entertainment's (CZR) CEO Mark Frissora on Q1 2018 Results - Earnings Call Transcript

2018-05-03 seekingalpha
Hello, and welcome to today’s webcast. My name is Cristina, and I will be your event specialist today. [Operator Instructions] Please note that today’s webcast is being recorded. [Operator Instructions] (9-0)

CUSIP: 12768T103